The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

A thick layer of more than 12 miles of rock may explain why Bermuda seems to float above the surrounding ocean. When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

After weeks of what had been tightly buttoned talks between the parties, Senate Democrats have delivered their latest counteroffer on the crypto market structure bill, outlining a set of demands ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

OpenAI announced Tuesday morning that it had completed a tumultuous corporate restructuring effort, simplifying a complex ownership web into a controlling nonprofit entity and a reimagined for-profit ...

Researchers at the Biocatalysis group led by Dr Francesco Mutti at the Van ‘t Hoff Institute for Molecular Sciences (University of Amsterdam) have developed a novel use of alcohol dehydrogenase (ADH) ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Neurological diseases and neural injuries are prevalent but difficult to treat because ...

How did the building blocks of life come together to spawn the first organisms? It’s one of the most longstanding questions in biology — and scientists just got a major clue. In a new study published ...

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...